Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock Price Up 4.6% - What's Next?

Key Points

• Chugai Pharmaceutical's stock price increased by 4.6% on Monday, closing at $24.93 after reaching a high of $25.70.
• Trading volume surged to 454,390 shares, an increase of 229% compared to the average daily volume of 138,189 shares.
• The company reported a quarterly earnings per share of $0.20 with revenue of $2.01 billion, showcasing a net margin of 33.08% and return on equity of 20.80%.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s share price rose 4.6% on Monday . The stock traded as high as $25.70 and last traded at $24.93. Approximately 454,390 shares traded hands during mid-day trading, an increase of 229% from the average daily volume of 138,189 shares. The stock had previously closed at $23.84.

Chugai Pharmaceutical Price Performance

The firm has a market capitalization of $82.05 billion, a P/E ratio of 31.56 and a beta of 0.64. The firm's 50 day simple moving average is $22.55 and its two-hundred day simple moving average is $24.40.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. The business had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. As a group, equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.